Diagnostic challenges in primary cardiac lymphoma, the opportunity of
Angiosarcoma
Cardiac tumors
Lymphoma
PET/CT
Tomography
X-ray computed
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
02
2021
accepted:
22
06
2021
pubmed:
29
7
2021
medline:
15
10
2022
entrez:
28
7
2021
Statut:
ppublish
Résumé
The purpose of this study was to retrospectively evaluate the value of Clinical and imaging data of patients with PCLs and PCAs were collected. All patients underwent preoperative Nine patients with PCL and eight patients with PCA were analyzed. There were significant differences in SUVmax (t = 3.790, P = .002), SUVmean (t = 4.273, P = .001), metabolic tumor volume (U = 13.00, P = .027), tumor-to-liver ratio (U = 10.00, P = .011), and total lesion glycolysis (U = 4.0, P = .001) between PCLs and PC The intensity- and volume-based PET parameters of PCL were significantly higher than those of PCA. The enhancement pattern and tumor morphology were also different. According to these characteristics, the two most common types of primary cardiac malignancies can be differentiated.
Sections du résumé
BACKGROUND
The purpose of this study was to retrospectively evaluate the value of
METHODS
Clinical and imaging data of patients with PCLs and PCAs were collected. All patients underwent preoperative
RESULTS
Nine patients with PCL and eight patients with PCA were analyzed. There were significant differences in SUVmax (t = 3.790, P = .002), SUVmean (t = 4.273, P = .001), metabolic tumor volume (U = 13.00, P = .027), tumor-to-liver ratio (U = 10.00, P = .011), and total lesion glycolysis (U = 4.0, P = .001) between PCLs and PC
CONCLUSION
The intensity- and volume-based PET parameters of PCL were significantly higher than those of PCA. The enhancement pattern and tumor morphology were also different. According to these characteristics, the two most common types of primary cardiac malignancies can be differentiated.
Identifiants
pubmed: 34318397
doi: 10.1007/s12350-021-02723-6
pii: 10.1007/s12350-021-02723-6
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2378-2389Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. American Society of Nuclear Cardiology.
Références
Roberts WC. Primary and secondary neoplasms of the heart. Am J Cardiol 1997;80:671-82.
doi: 10.1016/S0002-9149(97)00587-0
Gowda RM, Khan IA. Clinical perspectives of primary cardiac lymphoma. Angiology 2003;54:599-604.
doi: 10.1177/000331970305400510
Nascimento AF, Winters GL, Pinkus GS. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder. Am J Surg Pathol 2007;31:1344-50.
doi: 10.1097/PAS.0b013e3180317341
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumors of the lung, pleura, thymus and heart, vol. 4. Lyon: IRAC; 2015. p. 340.
Burke A, Tavora F. The 2015 WHO classification of tumors of the heart and pericardium. J Thorac Oncol 2016;11:441-52.
doi: 10.1016/j.jtho.2015.11.009
Maleszewski JJ, Bois MC, Bois JP, Young PM, Stulak JM, Klarich KW. Neoplasia and the heart: Pathological review of effects with clinical and radiological correlation. J Am Coll Cardiol 2018;72:202-27.
doi: 10.1016/j.jacc.2018.05.026
Cichowska-Cwalińska N, Dutka M, Klapkowski A, Pęksa R, Maciej Zaucha J, Zaucha R. The role of radiotherapy in the management of primary cardiac lymphoma a case report and the literature review. Leuk Lymphoma 2019;60:812-6.
doi: 10.1080/10428194.2018.1509321
Bonou M, Kapelios CJ, Marinakos A, Adamopoulos S, Diamantopoulos P, Foukas PG, et al. Diagnosis and treatment complications of primary cardiac lymphoma in an immunocompetent 28-year old man: a case report. BMC Cancer 2019;19(1):191. https://doi.org/10.1186/s12885-019-5405-y .
doi: 10.1186/s12885-019-5405-y
pubmed: 30823905
pmcid: 6397455
Jeudy J, Burke AP, Frazier AA. Cardiac lymphoma. Radiol Clin N Am 2016;54:689-710.
doi: 10.1016/j.rcl.2016.03.006
Miguel CE, Bestetti RB. Primary cardiac lymphoma. Int J Cardiol 2011;149:358-63.
doi: 10.1016/j.ijcard.2010.02.016
Xiao M, Lin J, Xiao T, Lin Y, Ye Y. The incidence and survival outcomes of patients with primary cardiac lymphoma: A SEER-based analysis. Hematol Oncol 2020;38:334-43.
doi: 10.1002/hon.2741
Wang SC, Pan CW. Overcoming the diagnostic challenges in a high-risk invasive primary cardiac lymphoma. Eur Heart J Cardiovasc Imaging 2020;21:707.
doi: 10.1093/ehjci/jez324
Burke A, Jeudy J, Virmani R. Cardiac tumours: an update: Cardiac tumours. Heart 2008;94:117-23.
doi: 10.1136/hrt.2005.078576
Colin GC, Symons R, Dymarkowski S, Gerber B, Bogaert J. Value of CMR to differentiate cardiac angiosarcoma from cardiac lymphoma. JACC Cardiovasc Imaging 2015;8:744-6.
doi: 10.1016/j.jcmg.2014.08.011
Liu ET, Sun TT, Dong HJ, Wang SY, Chen ZR, Liu C, et al. Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients. EJNMMI Res 2020;10:75. https://doi.org/10.1186/s13550-020-00661-x .
doi: 10.1186/s13550-020-00661-x
pubmed: 32632639
pmcid: 7338301
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-54.
doi: 10.1007/s00259-014-2961-x
Sher A, Lacoeuille F, Fosse P, Vervueren L, Cahouet-Vannier A, Dabli D, et al. For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET/CT quantification, regardless of acquisition time. EJNMMI Res 2016;6:21. https://doi.org/10.1186/s13550-016-0177-8 .
doi: 10.1186/s13550-016-0177-8
pubmed: 26944734
pmcid: 4779086
Kang J-H, Youk JH, Kim J-A, Gweon HM, Eun NL, Ko KH, et al. Identification of preoperative magnetic resonance imaging features associated with positive resection margins in breast cancer: A retrospective study. Korean J Radiol 2018;19:897-904.
doi: 10.3348/kjr.2018.19.5.897
Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Tiemann K, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med 2012;53:856-63.
doi: 10.2967/jnumed.111.095364
Qin C, Shao F, Hu F, Song W, Song Y, Guo J, et al. 18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: A retrospective study. Eur J Nucl Med Mol Imaging 2020;47:1083-93.
doi: 10.1007/s00259-019-04632-w
Meng J, Zhao H, Liu Y, Chen D, Hacker M, Wei Y, et al. Assessment of cardiac tumors by 18F-FDG PET/CT imaging: Histological correlation and clinical outcomes. J Nucl Cardiol 2020. https://doi.org/10.1007/s12350-019-02022-1 .
doi: 10.1007/s12350-019-02022-1
pubmed: 31933156
Kikuchi Y, Oyama-Manabe N, Manabe O, Naya M, Ito YM, Hatanaka KC, et al. Imaging characteristics of cardiac dominant diffuse large B-cell lymphoma demonstrated with MDCT and PET/CT. Eur J Nucl Med Mol Imaging 2013;40:1337-44.
doi: 10.1007/s00259-013-2436-5
Bligh MP, Borgaonkar JN, Burrell SC, MacDonald DA, Manos D. Spectrum of CT findings in thoracic extranodal non-hodgkin lymphoma. Radiographics 2017;37:439-61.
doi: 10.1148/rg.2017160077
Chikata A, Sakagami S, Kanamori N, Kato C, Omi W, Saeki T, et al. Coronary vessel floating sign and vasospastic angina in a patient with cardiac lymphoma. Int J Cardiol 2014;176:e20-5. https://doi.org/10.1016/j.ijcard.2014.06.081 .
doi: 10.1016/j.ijcard.2014.06.081
pubmed: 25049011
Yoshihara S, Sugimoto Y, Matsunaga M, Suzuki S, Tanioka F. Coronary vessel floating sign in cardiac diffuse large B-cell lymphoma. Eur Heart J Cardiovasc Imaging 2020;21:233. https://doi.org/10.1093/ehjci/jez190 .
doi: 10.1093/ehjci/jez190
pubmed: 31326994
Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016;23:1187-226.
doi: 10.1007/s12350-016-0522-3